Welcome!

News Feed Item

Lilly To Release Early-Stage Pipeline Data Targeting Key Cancer Pathways At AACR 2014

INDIANAPOLIS, April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.

"Harnessing Breakthroughs – Targeting Cures" is the theme of this year's AACR meeting and one that is mirrored throughout Lilly's early-stage oncology research. Lilly's oncology pipeline is among the most robust across the pharmaceutical industry and includes a broad range of large and small molecules being investigated to treat a wide range of cancers including lung, breast, colorectal, gastric, liver and hematologic malignancies. Lilly research presented at AACR will represent early findings from several of those early-stage clinical agents.

Data from bemaciclib, Lilly's CDK4/6 inhibitor LY2835219 as a potential treatment for metastatic breast cancer, has been accepted as a late-breaking presentation that will be included at AACR's Clinical Trials Symposium and will be featured in an official AACR-sponsored press conference.

"The CDK4/6 pathway is one of the most commonly implicated pathways in all cancers, making it an important area for research," said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology. "The single-agent activity we've observed for bemaciclib is encouraging in this setting and we believe the data support the need for further development in metastatic breast cancer."

Lilly's B-Raf inhibitor LY3009120 will be highlighted at AACR's New Drugs on the Horizon special session where first data disclosures of promising, new anti-cancer compounds that target key pathways will occur. There will also be an oral presentation on Lilly's c-MET kinase inhibitor, LY2801653.

"As we gain a better understanding about the distinct tumor biologies and other individual characteristics that make one tumor different than another, we are able to apply this knowledge to our development of potential new cancer treatments, such as those we are presenting at AACR," said Dr. Gaynor. "Each step we take during early-stage research – both in the lab and on clinical trials – leads us toward the same overall goal: to increase the number of treatment options available to patients."

Select Lilly early-stage pipeline studies, along with the times and locations of their data sessions, are highlighted below.

bemaciclib (LY2835219)

  • Abstract #CT232: Clinical Trials Symposium: Monday, April 7, 2014 1:30 pm1:50 pm
    • Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
    • Author/Speaker: Amita Patnaik, M.D., FRCP(C)
    • Location: Room 25
    • Note: Abstract #CT232 to be presented at AACR press conference on April 6 at 7:30 am

B-Raf Inhibitor (LY3009120)

  • Abstract #7135: New Drugs on the Horizon Special Session: Sunday, April 6, 2014 3:45 pm to 4:10 pm
    • Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimer with activity against BRaf or Ras mutant tumor cells and minimal paradoxical activation
    • Author/Speaker: Sheng-Bin Peng, Ph.D.
    • Location: Room 29

c-MET Inhibitor (LY2801653)

  • Abstract #CT237: Clinical Trials Minisymposium: Monday, April 7, 2014 3:20 pm3:35 pm
    • Interim results of a first-in-human Phase I study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer
    • Author/Speaker: Jimmy Hwang, M.D.
    • Location: Room 29
  • Abstract #4403: Poster Presentation: Tuesday April 8, 2014 1:00 pm to 5:00 pm
    • Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models
    • Author/Speaker: S. Betty Yan, Ph.D.
    • Location: Hall A-E, Section 24

FGFR Inhibitor (LY2874455)

  • Abstract #CT215: Poster Presentation: Monday, April 7, 2014 8:00 am to 12:00 pm
    • A Phase 1 Study of LY2874455, a Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Cancer
    • Author/Speaker: Dr. Jeanne Tie
    • Location: Hall A-E, Section 38

P-LLY

This press release contains forward-looking statements about the potential of LY2835219, LY2801653, LY3009120 and LY2874455 as treatments for various cancers and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results for these products will be consistent with study findings to date, that these products will receive regulatory approvals, or will prove to  be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Media Inquiries:


Keri McGrath, Lilly Oncology

Neil Hochman, TogoRun

317-370-8394 (mobile)

212-453-2067 (office) / 516-784-9089 (mobile)

Email: [email protected]

Email: [email protected]

 

Eli Lilly and Company logo

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

 

SOURCE Eli Lilly and Company

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Open Source Software development, collaboration, discovery and download on the web serving over 32 million viewers, 150 million downloads and over 460,000 active development projects each and every month.
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
As popularity of the smart home is growing and continues to go mainstream, technological factors play a greater role. The IoT protocol houses the interoperability battery consumption, security, and configuration of a smart home device, and it can be difficult for companies to choose the right kind for their product. For both DIY and professionally installed smart homes, developers need to consider each of these elements for their product to be successful in the market and current smart homes.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
In the fast-paced advances and popularity in cloud technology, one of the most critical factors revolves around concerns for security of your critical data. How to assure both your company and your customers they can confidently trust and utilize your cloud environment is most often top on the list. There is a method to evaluating and providing security that exceeds conventional modes of protecting data both within the cloud as well externally on mobile and other devices. With the public failure...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Transforming cloud-based data into a reportable format can be a very expensive, time-intensive and complex operation. As a SaaS platform with more than 30 million global users, Cornerstone OnDemand’s challenge was to create a scalable solution that would improve the time it took customers to access their user data. Our Real-Time Data Warehouse (RTDW) process vastly reduced data time-to-availability from 24 hours to just 10 minutes. In his session at 21st Cloud Expo, Mark Goldin, Chief Technolo...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, will discuss how from store operations...
Though cloud is the future of enterprise computing, a smooth transition of legacy applications and systems is critical for seamless business operations. IT professionals are eager to start leveraging the cost, scale and other benefits of cloud, but with massive investments already in place in existing infrastructure and a number of compliance and resource hurdles, it can be challenging to move to a cloud-based infrastructure.